Literature DB >> 28725168

Comprehensive Registry of Esophageal Cancer in Japan, 2010.

Yuji Tachimori1, Soji Ozawa2, Hodaka Numasaki3, Ryu Ishihara4, Hisahiro Matsubara5, Kei Muro6, Tsuneo Oyama7, Yasushi Toh8, Harushi Udagawa9, Takashi Uno10.   

Abstract

Entities:  

Year:  2017        PMID: 28725168      PMCID: PMC5486463          DOI: 10.1007/s10388-017-0578-4

Source DB:  PubMed          Journal:  Esophagus        ISSN: 1612-9059            Impact factor:   4.230


× No keyword cloud information.

Preface 2010

We deeply appreciate the great contributions of many physicians in the registry of esophageal cancer cases. The Comprehensive Registry of Esophageal Cancer in Japan, 2010, was published here, despite some delay. The registry complies with the Act for the Protection of Personal Information. The encryption with a HASH function is used for ‘‘anonymity in an unlinkable fashion’’. We briefly summarized the Comprehensive Registry of Esophageal Cancer in Japan, 2010. Japanese Classification of Esophageal Cancer 10th and UICC TNM Classification 7th were used for cancer staging according to the subjected year. A total of 5878 cases were registered from 280 institutions in Japan. Tumor locations were cervical: 4.3%, upper thoracic: 12.7%, middle thoracic: 48.8%, lower thoracic: 26.5% and EG junction: 6.5%. Superficial carcinomas (Tis, T1a, T1b) were 34.9%. As for the histologic type of biopsy specimens, squamous cell carcinoma and adenocarcinoma accounted for 90.5 and 4.0%, respectively. Regarding clinical results, the 5-year survival rates of patients treated using endoscopic mucosal resection, concurrent chemoradiotherapy, or esophagectomy were 85.5, 27.3, and 55.5%, respectively. Esophagectomy was performed in 3564 cases. Concerning the approach used for esophagectomy, 30.4% of the cases were treated thoracoscopically. The operative mortality (within 30 days after surgery) was 0.61% and the hospital mortality was 4.29%. We hope that this Comprehensive Registry of Esophageal Cancer in Japan for 2010 will help to improve all aspects of the diagnosis and treatment of esophageal cancer in Japan.

Contents

I. Clinical factors of esophageal cancer patients treated in 2010 Institution-registered cases in 2010 Patient background Table Age and gender
Table 1

Age and gender

AgeMaleFemaleUnknownCases (%)
≤29112 (0.0%)
30–3914418 (0.3%)
40–4912544169 (2.9%)
50–598021451948 (16.1%)
60–69214029112432 (41.4%)
70–7915962671863 (31.7%)
80–8934278420 (7.1%)
≥908715 (0.3%)
Unknown10111 (0.2%)
Total503883825878
Table Primary treatment
Table 2

Primary treatment

TreatmentsCases (%)
Surgery3638 (61.9%)
 Esophagectomy3564 (60.6%)
 Palliative74 (1.3%)
Chemotherapy/radiotherapy1413 (24.0%)
Endoscopic treatment827 (14.1%)
Total5878
Table Tumor location
Table 3

Tumor location

Location of tumorEndoscopic treatment (%)SurgeryChemotherapy and/or radiotherapy (%)Total (%)
Esophagectomy (%)Palliative surgery (%)
Cervical18 (2.2%)116 (3.3%)6 (8.1%)114 (8.1%)254 (4.3%)
Upper thoracic90 (10.9%)411 (11.5%)15 (20.3%)233 (16.5%)749 (12.7%)
Middle thoracic483 (58.4%)1669 (46.8%)39 (52.7%)677 (47.9%)2868 (48.8%)
Lower thoracic186 (22.5%)1054 (29.6%)12 (16.2%)303 (21.4%)1555 (26.5%)
EG34 (4.1%)241 (6.8%)1 (1.4%)31 (2.2%)307 (5.2%)
E = G1 (0.1%)38 (1.1%)1 (1.4%)1 (0.1%)41 (0.7%)
GE3 (0.4%) 27 (0.8%)6 (0.4%)36 (0.6%)
Unknown12 (1.5%)8 (0.2%)48 (3.4%)68 (1.2%)
Total82735647414135878

E esophageal, G gastric

Table Histologic types of biopsy specimens
Table 4

Histologic types of biopsy specimens

Histologic typesCases (%)
Squamous cell carcinoma5320 (90.5%)
 Squamous cell carcinoma3581 (60.9%)
 Well differentiated334 (5.7%)
 Moderately differentiated1072 (18.2%)
 Poorly differentiated333 (5.7%)
Adenocarcinoma233 (4.0%)
Barrett’s adenocarcinoma64 (1.1%)
Adenosquamous carcinoma8 (0.1%)
Mucoepidermoid carcinoma2 (0.0%)
Basaloid carcinoma27 (0.5%)
Endocrine cell carcinoma13 (0.2%)
Undifferentiated carcinoma10 (0.2%)
Sarcoma2 (0.0%)
Malignant melanoma16 (0.3%)
Carcinosarcoma9 (0.2%)
GIST1 (0.0%)
Other tumors34 (0.6%)
Unknown139 (2.4%)
Total5878
Table Depth of tumor invasion, cT (UICC TNM 7th)
Table 5

Depth of tumor invasion, cT (UICC TNM 7th)

cTCases (%)
cTX16 (0.3%)
cT09 (0.2%)
cTis144 (2.4%)
cT1a780 (13.3%)
cT1b1130 (19.2%)
cT2813 (13.8%)
cT32134 (36.3%)
cT4a357 (6.1%)
cT4b410 (7.0%)
Unknown85 (1.4%)
Total5878
Table Lymph node metastasis, cN (UICC TNM 7th)
Table 6

Lymph node metastasis, cN (UICC TNM 7th)

cNCases (%)
cNX88 (1.5%)
cN02646 (45.0%)
cN11642 (27.9%)
cN2986 (16.8%)
cN3342 (5.8%)
Unknown174 (3.0%)
Total5878
Table Distant metastasis, cM (UICC TNM 7th)
Table 7

Distant metastasis, cM (UICC TNM 7th)

cMCases (%)
cM05091 (86.6%)
cM1652 (11.1%)
Unknown135 (2.3%)
Total5878
Table Clinical Stage (UICC TNM 7th)
Table 8

Clinical Stage (UICC TNM 7th)

Clinical stageEndoscopic treatment (%)SurgeryChemotherapy and/or radiotherapy (%)Total (%)
Esophagectomy (%)Palliative surgery (%)
0112 (13.5%)12 (0.3%)1 (0.1%)125 (2.1%)
IA563 (68.1%)862 (24.2%)158 (11.2%)1583 (26.9%)
IB4 (0.5%)299 (8.4%)2 (2.7%)68 (4.8%)373 (6.3%)
IIA2 (0.2%)336 (9.4%)7 (9.5%)49 (3.5%)394 (6.7%)
IIB2 (0.2%)378 (10.6%)2 (2.7%)64 (4.5%)446 (7.6%)
IIIA7 (0.8%)783 (22.0%)12 (16.2%)165 (11.7%)967 (16.5%)
IIIB5 (0.6%)354 (9.9%)13 (17.6%)92 (6.5%)464 (7.9%)
IIIC25 (3.0%)241 (6.8%)22 (29.7%)315 (22.3%)603 (10.3%)
IV31 (3.7%)145 (4.1%)12 (16.2%)409 (28.9%)597 (10.2%)
Unknown76 (9.2%)154 (4.3%)4 (5.4%)92 (6.5%)326 (5.5%)
Total82735647414135878
Results of endoscopically treated patients in 2010 Table Details of endoscopic treatment
Table 9

Details of endoscopic treatment

Treatment detailsCases (%)
EMR59 (7.8%)
EMR + YAG laser6 (0.8%)
ESD667 (88.5%)
ESD + EMR6 (0.8%)
ESD + PDT4 (0.5%)
ESD + YAG laser1 (0.1%)
PDT3 (0.4%)
YAG laser8 (1.1%)
Total754

EMR endoscopic mucosal resection, ESD endoscopic submucosal dissection, YAG yttrium aluminum garnet, PDT photodynamic therapy

Table Complications of EMR/ESD
Table 10

Complications of EMR/ESD

Complications of EMR/ESDCases (%)
None672 (90.4%)
Perforation13 (1.7%)
Bleeding2 (0.3%)
Mediastinitis4 (0.5%)
Stenosis44 (5.9%)
Others8 (1.1%)
Total743
Table Pathological depth of tumor invasion of EMR/ESD specimens
Table 11

Pathological depth of tumor invasion of EMR/ESD specimens

Pathological depth of tumor invasion (pT)Cases (%)
pTX1 (0.1%)
pT07 (0.9%)
pTis163 (21.9%)
pT1a482 (64.9%)
pT1b74 (10.0%)
pT21 (0.1%)
Unknown15 (2.0%)
Total743
Figure Survival of patients treated with EMR/ESD
Fig. 1

Survival of patients treated with EMR/ESD

Survival of patients treated with EMR/ESD Figure Survival of patients treated with EMR/ESD according to the pathological depth of tumor invasion (pT)
Fig. 2

Survival of patients treated with EMR/ESD according to the pathological depth of tumor invasion (pT)

Survival of patients treated with EMR/ESD according to the pathological depth of tumor invasion (pT) Figure Survival of patients treated with EMR/ESD according to the lymphatic and venous invasion
Fig. 3

Survival of patients treated with EMR/ESD according to the lymphatic and venous invasion

Survival of patients treated with EMR/ESD according to the lymphatic and venous invasion Results in patients treated with chemotherapy and/or radiotherapy in 2010 Table Dose of irradiation (non-surgically treated cases)
Table 12

Dose of irradiation (non-surgically treated cases)

Dose of irradiation (Gy)DefinitivePalliative (%)Recurrence (%)Others (%)Unknown (%)Total (%)
Radiation alone (%)With chemotherapy (%)
≤295 (2.9%)10 (1.4%)26 (9.2%)1 (2.7%)42 (3.5%)
30–391 (0.6%)7 (1.0%)43 (15.1%)3 (10.0%)4 (10.8%)58 (4.8%)
40–499 (5.3%)24 (3.5%)36 (12.7%)1 (3.3%)10 (27.0%)80 (6.6%)
50–5927 (15.9%)173 (25.0%)60 (21.1%)9 (30.0%)13 (35.1%)1 (33.3%)283 (23.3%)
60–69124 (72.9%)453 (65.5%)109 (38.4%)17 (56.7%)9 (24.3%)2 (66.7%)714 (58.7%)
≥704 (7.2%)14 (2.1%)5 (0.0%)23 (2.2%)
Unknown11 (1.6%)5 (1.8%)16 (1.3%)
Total170692284303731216
Median (min–max)60.0 (2.0–105.0)60.0 (1.8–72.0)52.5 (1.8–90.0)60.0 (37.5–67.0)50.0 (9.0–66.0)60.0 (52.0–60.0)60.0 (1.8–105.0)
Table Dose of irradiation (surgically treated cases)
Table 13

Dose of irradiation (surgically treated cases)

Dose of irradiation (Gy)Preoperative irradiation (%)Postoperative irradiation (%)
≤292 (1.0%)
30–3934 (17.5%)1 (2.1%)
40–49132 (68.0%)10 (21.3%)
50–597 (3.6%)12 (25.5%)
60–6913 (6.7%)22 (46.8%)
≥702 (1.1%)
Unknown6 (3.1%)
Total19447
Median (min–max)40.0 (0.0–66.0)60.0 (30.0–79.2)
Figure Survival of patients treated with chemotherapy and/or radiotherapy
Fig. 4

Survival of patients treated with chemotherapy and/or radiotherapy

Survival of patients treated with chemotherapy and/or radiotherapy Figure Survival of patients treated with definitive chemoradiotherapy according to clinical stage (UICC TNM 7th)
Fig. 5

Survival of patients treated with definitive chemoradiotherapy according to clinical stage (UICC TNM 7th)

Survival of patients treated with definitive chemoradiotherapy according to clinical stage (UICC TNM 7th) Results in patients who underwent esophagectomy in 2010 Table Treatment modalities of esophagectomy
Table 14

Treatment modalities of esophagectomy

TreatmentsCases (%)
Esophagectomy alone1463 (41.0%)
Esophagectomy + endoscopic treatment83 (2.3%)
Esophagectomy + chemoradiotherapy571 (16.0%)
 Concurrent chemoradiotherapy502 (14.1%)
 Other69 (1.9%)
Esophagectomy + chemoradiotherapy + endoscopic treatment13 (0.4%)
Esophagectomy + chemotherapy1391 (39.0%)
 Preoperative1027 (28.8%)
 Postoperative183 (5.1%)
 Pre and postoperative75 (2.1%)
 Recurrence46 (1.3%)
 Other60 (1.7%)
Esophagectomy + chemotherapy + endoscopic treatment3 (0.1%)
Esophagectomy + radiotherapy39 (1.1%)
 Preoperative4 (0.1%)
 Postoperative7 (0.2%)
 Recurrence15 (0.4%)
 Other13 (0.4%)
Esophagectomy + radiotherapy + endoscopic treatment1 (0.0%)
Total3564
Table Tumor location
Table 15

Tumor location

LocationsCases (%)
Cervical116 (3.3%)
Upper thoracic411 (11.5%)
Middle thoracic1669 (46.8%)
Lower thoracic1054 (29.6%)
E > G241 (6.8%)
E = G38 (1.1%)
G > E27 (0.8%)
Unknown8 (0.2%)
Total lesions3564
Table Approaches to tumor resection
Table 16

Approaches to tumor resection

ApproachesCases (%)
Cervical approach150 (4.2%)
Right thoracotomy3010 (84.5%)
Left thoracotomy50 (1.4%)
Left thoracoabdominal approach58 (1.6%)
Laparotomy108 (3.0%)
Transhiatal thoracic esophagectomy50 (1.4%)
Transhiatal lower esophagectomy72 (2.0%)
Sternotomy4 (0.1%)
Others28 (0.8%)
Unknown34 (1.0%)
Total3564
Table Video-assisted surgery
Table 17

Video-assisted surgery

Video-assisted surgeryCases (%)
None2117 (59.4%)
Thoracoscopy653 (18.3%)
Thoracoscopy + laparoscopy431 (12.1%)
Thoracoscopy + laparoscopy + mediastinoscopy1 (0.0%)
Thoracoscopy + laparoscopy + other1 (0.0%)
Laparoscopy104 (2.9%)
Laparoscopy + mediastinoscopy8 (0.2%)
Laparoscopy + other1 (0.0%)
Mediastinoscopy4 (0.1%)
Others11 (0.3%)
Total3564
Table Fields of lymph node dissection according to the location of the tumor
Table 18

Fields of lymph node dissection according to the location of the tumor

Field of lymphadenectomyCervicalUpper thoracicMiddle thoracicLower thoracicE > GE = GG > EUnknownTotal
None10 (8.6%)13 (3.2%)59 (3.5%)28 (2.7%)13 (5.4%)2 (25.0%)125 (3.5%)
C36 (31.0%)10 (2.4%)20 (1.2%)3 (0.3%)1 (0.4%)70 (2.0%)
C + UM21 (18.1%)6 (1.5%)3 (0.2%)1 (0.1%)31 (0.9%)
C + UM + MLM2 (1.7%)12 (2.9%)28 (1.7%)12 (1.1%)1 (3.7%)55 (1.5%)
C + UM + MLM + A27 (23.3%)257 (62.5%)800 (47.9%)367 (34.8%)26 (10.8%)6 (15.8%)1 (12.5%)1484 (41.6%)
C + UM + MLM + A+OT1 (0.1%)1 (0.0%)
C + UM + A2 (1.7%)1 (0.2%)2 (0.1%)2 (0.2%)7 (0.2%)
C + MLM1 (0.1%)1 (0.0%)
C + MLM + A3 (2.6%)1 (0.2%)7 (0.4%)3 (0.3%)14 (0.4%)
C + A1 (0.9%)2 (0.5%)4 (0.2%)2 (0.2%)1 (0.4%)10 (0.3%)
UM4 (3.4%)3 (0.7%)5 (0.3%)3 (0.3%)15 (0.4%)
UM + MLM1 (0.9%)7 (1.7%)29 (1.7%)12 (1.1%)1 (0.4%)1 (12.5%)51 (1.4%)
UM + MLM + A3 (2.6%)75 (18.2%)627 (37.6%)478 (45.4%)56 (23.2%)5 (13.2%)1 (3.7%)1 (12.5%)1246 (35.0%)
UM + A1 (0.9%)4 (1.0%)2 (0.1%)2 (0.2%)2 (0.8%)11 (0.3%)
MLM3 (0.7%)10 (0.6%)14 (1.3%)3 (1.2%)30 (0.8%)
MLM + A1 (0.9%)7 (1.7%)34 (2.0%)102 (9.7%)108 (44.8%)23 (60.5%)17 (63.0%)292 (8.2%)
A1 (0.9%)6 (1.5%)22 (1.3%)12 (1.1%)28 (11.6%)3 (7.9%)8 (29.6%)1 (12.5%)81 (2.3%)
Unknown3 (2.6%)4 (1.0%)16 (1.0%)12 (1.1%)2 (0.8%)1 (2.6%)2 (25.0%)40 (1.1%)
Total11641116691054241382783564

C bilateral cervical nodes, UM upper mediastinal nodes, MLM middle-lower mediastinal nodes, A abdominal nodes

Table Reconstruction route
Table 19

Reconstruction route

Reconstruction routeCases (%)
None57 (1.6%)
Subcutaneous302 (8.5%)
Retrosternal1191 (33.4%)
Posterior mediastinal1473 (41.3%)
Intrathoracic435 (12.2%)
Cervical50 (1.4%)
Others34 (1.0%)
Unknown22 (0.6%)
Total3564
Table Organs used for reconstruction
Table 20

Organs used for reconstruction

Organs used for reconstructionCases (%)
None72 (2.0%)
Whole stomach71 (2.0%)
Gastric tube3059 (85.0%)
Jejunum176 (4.9%)
Free jejunum69 (1.9%)
Colon114 (3.2%)
Free colon10 (0.3%)
Others13 (0.4%)
Unknown16 (0.4%)
Total organs3600
Total cases3564
Table Histological classification
Table 21

Histological classification

Histological classificationCases (%)
Squamous cell carcinoma3045 (86.0%)
 Squamous cell carcinoma584 (16.5%)
 Well differentiated566 (16.0%)
 Moderately differentiated1445 (40.8%)
 Poorly differentiated450 (12.7%)
Adenocarcinoma161 (4.5%)
Barrett’s adenocarcinoma71 (2.0%)
Adenosquamous cell carcinoma20 (0.6%)
Mucoepidermoid carcinoma3 (0.1%)
Adenoid cystic carcinoma2 (0.1%)
Basaloid carcinoma71 (2.0%)
Endocrine cell carcinoma15 (0.4%)
Undifferentiated carcinoma6 (0.2%)
Other carcinoma14 (0.4%)
Carcinosarcoma18 (0.5%)
Malignant melanoma16 (0.5%)
GIST1 (0.0%)
Other33 (0.9%)
Unknown66 (1.9%)
Total3542
Table Depth of tumor invasion, pT (JES 10th)
Table 22

Depth of tumor invasion, pT (JES 10th)

pT categoryCases (%)
pTX25 (0.7%)
pT079 (2.2%)
pTis25 (0.7%)
pT1a373 (10.5%)
pT1b943 (26.5%)
pT2450 (12.6%)
pT31368 (38.4%)
pT4111 (3.1%)
pT4a34 (1.0%)
pT4b33 (0.9%)
Unknown123 (3.5%)
Total3564
Table Pathological grading of lymph node metastasis, pN (JES 10th)
Table 23

Pathological grading of lymph node metastasis, pN (JES 10th)

Lymph node metastasisCases (%)
pN02079 (58.3%)
pN1474 (13.3%)
pN2564 (15.8%)
pN3233 (6.5%)
pN4149 (4.2%)
Unknown65 (1.8%)
Total3564
Table Pathological findings of lymph node metastasis, pN (UICC 7th)
Table 24

Pathological findings of lymph node metastasis, pN (UICC 7th)

Lymph node metastasisCases (%)
pN01571 (44.1%)
pN1 (1–2)956 (26.8%)
pN2 (3–6)623 (17.5%)
pN3 (7–)351 (9.8%)
Unknown63 (1.8%)
Total3564

Regional lymph nodes are different in JES 10th and UICC 7th

Data for Tables 23 and 24 are analyzed from different variables in the registration application

Table Pathological findings of distant organ metastasis, pM (JES 10th)
Table 25

Pathological findings of distant organ metastasis, pM (JES 10th)

Distant metastasisCases (%)
pMX62 (1.7%)
pM03446 (96.7%)
pM156 (1.6%)
Total3564
Table Residual tumor
Table 26

Residual tumor

Residual tumorCases (%)
RX156 (4.1%)
R03345 (87.0%)
R1187 (4.9%)
R2156 (4.1%)
Total3844
Table Causes of death
Table 27

Causes of death

Cause of deathCases (%)
Death due to recurrence1139 (72.8%)
Death due to other cancer65 (4.2%)
Death due to other disease (rec+)44 (2.8%)
Death due to other disease (rec−)179 (11.4%)
Death due to other disease (rec?)7 (0.4%)
Operative death*39 (2.5%)
Postoperative hospital death**40 (2.6%)
Unknown52 (3.3%)
Total of death cases1565 (100%)

rec recurrence

* Operative death means death within 30 days after operation in or out of hospital

** Hospital death is defined as death during the same hospitalization, regardless of department at time of death

Operative mortality after esophagectomy: 0.61%

Hospital mortality after esophagectomy: 4.29%

Figure Survival of patients who underwent esophagectomy
Fig. 6

Survival of patients underwent esophagectomy

Survival of patients underwent esophagectomy Figure Survival of patients who underwent esophagectomy according to clinical stage (JES 10th)
Fig. 7

Survival of patients who underwent esophagectomy according to clinical stage (JES 10th)

Survival of patients who underwent esophagectomy according to clinical stage (JES 10th) Figure Survival of patients who underwent esophagectomy according to clinical stage (UICC 7th)
Fig. 8

Survival of patients who underwent esophagectomy according to clinical stage (UICC 7th)

Survival of patients who underwent esophagectomy according to clinical stage (UICC 7th) Figure Survival of patients who underwent esophagectomy according to the depth of tumor invasion, pT (JES 10th)
Fig. 9

Survival of patients who underwent esophagectomy according to the depth of tumor invasion, pT (JES 10th)

Survival of patients who underwent esophagectomy according to the depth of tumor invasion, pT (JES 10th) Figure Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (JES 10th)
Fig. 10

Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (JES 10th)

Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (JES 10th) Figure Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (UICC 7th)
Fig. 11

Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (UICC 7th)

Survival of patients who underwent esophagectomy according to lymph node metastasis, pN (UICC 7th) Figure Survival of patients who underwent esophagectomy according to pathological stage (JES 10th)
Fig. 12

Survival of patients who underwent esophagectomy according to pathological stage (JES 10th)

Survival of patients who underwent esophagectomy according to pathological stage (JES 10th) Figure Survival of patients who underwent esophagectomy according to pathological stage (UICC TNM 7th)
Fig. 13

Survival of patients who underwent esophagectomy according to pathological stage (UICC TNM 7th)

Survival of patients who underwent esophagectomy according to pathological stage (UICC TNM 7th) Figure Survival of patients who underwent esophagectomy according to residual tumor (R)
Fig. 14

Survival of patients who underwent esophagectomy according to residual tumor (R)

Survival of patients who underwent esophagectomy according to residual tumor (R)

I. Clinical factors of esophageal cancer patients treated in 2010

Institution-registered cases in 2010

(Total 280 institutions) Age and gender Primary treatment Tumor location E esophageal, G gastric Histologic types of biopsy specimens Depth of tumor invasion, cT (UICC TNM 7th) Lymph node metastasis, cN (UICC TNM 7th) Distant metastasis, cM (UICC TNM 7th) Clinical Stage (UICC TNM 7th) Details of endoscopic treatment EMR endoscopic mucosal resection, ESD endoscopic submucosal dissection, YAG yttrium aluminum garnet, PDT photodynamic therapy Complications of EMR/ESD Pathological depth of tumor invasion of EMR/ESD specimens Dose of irradiation (non-surgically treated cases) Dose of irradiation (surgically treated cases) Treatment modalities of esophagectomy Tumor location Approaches to tumor resection Video-assisted surgery Fields of lymph node dissection according to the location of the tumor C bilateral cervical nodes, UM upper mediastinal nodes, MLM middle-lower mediastinal nodes, A abdominal nodes Reconstruction route Organs used for reconstruction Histological classification Depth of tumor invasion, pT (JES 10th) Pathological grading of lymph node metastasis, pN (JES 10th) Pathological findings of lymph node metastasis, pN (UICC 7th) Regional lymph nodes are different in JES 10th and UICC 7th Data for Tables 23 and 24 are analyzed from different variables in the registration application Pathological findings of distant organ metastasis, pM (JES 10th) Residual tumor Causes of death rec recurrence * Operative death means death within 30 days after operation in or out of hospital ** Hospital death is defined as death during the same hospitalization, regardless of department at time of death Operative mortality after esophagectomy: 0.61% Hospital mortality after esophagectomy: 4.29%
Institution
Aichi Cancer Center
Aichi Medical University Hospital
Aizawa Hospital
Akita Kouseiren Hiraka Hospital
Akita University Hospital
Arao Municipal Hospital
Asahikawa Medical College Hospital
Chiba Aoba Municipal Hospital
Chiba Cancer Center
Chiba Medical Center
Chiba Prefectural Sawara Hospital
Chiba University Hospital
Chibaken Saiseikai Narashino Hospital
Dokkyo Medical University Hospital
Ehime University Hospital
Foundation for Detection of Early Gastric Carcinoma
Fuchu Hospital
Fujioka General Hospital
Fujisawa Shounandai Hospital
Fujita Health University
Fukui Prefectural Hospital
Fukui University Hospital
Fukuoka Dental College and Dental Hospital
Fukuoka Saiseikai General Hospital
Fukuoka University Chikushi Hospital
Fukuoka University Hospital
Fukuoka Wajiro Hospital
Fukushima Medical University Hospital
Fukuyama City Hospital
Fussa Hospital
Gifu Prefectural General Medical Center
Gifu University Hospital
Gunma Central General Hospital
Gunma Prefectural Cancer Center
Gunma University Hospital
Gunmaken Saiseikai Maebashi Hospital
Hachinohe City Hospital
Hakodate Goryokaku Hospital
Hakodate National Hospital
Hamamatsu University School of Medicine, University Hospital
Hannan Chuo Hospital
Heartlife Hospital
Higashiosaka City General Hospital
Hiratsuka City Hospital
Hiratsuka Kyosai Hospital
Hirosaki University Hospital
Hiroshima City Asa Hospital
Hiroshima University Research Institute for Radiation Biology Medicine
Hofu Institute of Gastroenterology
Hokkaido Kin-Ikyo Chuo Hospital
Hokkaido University Hospital
Hyogo Cancer Center
Hyogo College of Medicine
Hyogo Prefectural Nishinomiya Hospital
Ibaraki Prefectural Central Hospital
Iizuka Hospital
Ikeda Municipal Hospital
Imazu Surgical Clinic
Inazawa City Hospital
International University of Health and Welfare Hospital
International University of Health and Welfare, Mita Hospital
Isehara Kyodo Hospital
Ishikawa Prefectural Central Hospital
Iwakuni Medical Center
Iwate Medical University Hospital
Iwate Prefectural Chubu Hospital
Japanese Red Cross Fukui Hospital
Japanese Red Cross Ishinomaki Hospital
Japanese Red Cross Kyoto Daini Hospital?
Japanese Red Cross Maebashi Hospital
Japanese Red Cross Nagaoka Hospital
Japanese Red Cross Okayama Hospital
Japanese Red Cross Society Azumino Hospital
Japanese Red Cross Tottori Hospital
Jichi Medical University Hospital
Juntendo University Hospital
Juntendo University Shizuoka Hospital
Junwakai Memorial Hospital
Kagawa Prefectural Central Hospital
Kagawa Rosai Hospital
Kagawa University Hospital
Kagoshima Kenritsu Satsunan Hospital
Kagoshima University Hospital
Kameda General Hospital
Kanagawa Cancer Center
Kanazawa Medical University Hospital
Kanazawa University Hospital
Kansai Medical University Hirakata Hospital
Kansai Medical University Medical Center
Kansai Rosai Hospital
Kasamatsu Hospital
Kashiwa Kousei General Hospital
Kawakita General Hospital
Kawasaki Medical School Hospital
Kawasaki Medical School Kawasaki Hospital
Kawasaki Municipal Ida Hospital
Keio University Hospital
Keiyukai Sapporo Hospital
Kikuna Memorial Hospital
Kinki Central Hospital
Kinki University Hospital
Kiryu Kosei General Hospital
Kishiwada City Hospital
Kitaakita Municipal Hospital
Kitakyushu Municipal Medical Center
Kitano Hospital
Kobe City Medical Center General Hospital
Kobe University Hospital
Kochi Health Science Center
Kochi University Hospital
Kokura Memorial Hospital
Kumamoto City Hospital
Kumamoto University Hospital
Kurashiki Central Hospital
Kurume General Hospital
Kurume University Hospital
Kyoto University Hospital
Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers
Kyushu Hospital
Kyushu Medical Center
Kyushu University Hospital
Machida Municipal Hospital
Matsuda Hospital
Matsushita Memorial Hospital
Matsuyama Red Cross Hospital
Mie University Hospital
Mino City Hospital
Mito Red Cross Hospital
Mitsui Memorial Hospital
Miyazaki Konan Hospital
Murakami General Hospital
Musashino Red Cross Hospital
Nagahama City Hospital
Nagano Red Cross Hospital
Nagaoka Chuo General Hospital
Nagasaki University Hospital
Nagayoshi General Hospital
Nagoya City University Hospital
Nagoya City West Medical Center
Nagoya Daiichi Red Cross Hospital
Nagoya University Hospital
Nanpuh Hospital
Nara Hospital Kinki University Faculty of Medicine
Nara Medical University Hospital
National Cancer Center Hospital
National Cancer Center Hospital East
National Defense Medical College Hospital
National Hospital Organization Beppu Medical Center
National Hospital Organization Chiba-East-Hospital
National Hospital Organization Fukuoka-Higashi Medical Center
National Hospital Organization Iwakuni Medical Center
National Hospital Organization Kure Medical Center
National Hospital Organization Kyoto Medical Center
National Hospital Organization Kyushu Cancer Center
National Hospital Organization Matsumoto National Hospital
National Hospital Organization Nagasaki Medical Center
National Hospital Organization Nagoya Medical Center
National Hospital Organization Osaka National Hospital
National Hospital Organization Tokyo Medical Center
Niigata Cancer Center Hospital
Niigata City General Hospital
Niigata Prefectural Shibata Hospital
Niigata University Medical and Dental Hospital
Nikko Memorial Hospital
Nippon Medical School Chiba Hokusoh Hospital
Nippon Medical School Hospital
Nippon Medical School Musashi Kosugi Hospital
Nippon Medical School Tama Nagayama Hospital
Nishi-Kobe Medical Center
Nishinomiya Municipal Central Hospital
Numazu City Hospital
Obihiro Kousei General Hospital
Obitsusankei Hospital
Ohta General Hospital Foundation Ohta Nishinouchi Hospital
Oita Red Cross Hospital
Oita University Hospital
Okayama Saiseikai General Hospital
Okayama University Hospital
Omuta City Hospital
Osaka City University Hospital
Osaka Hospital of Japan Seafarers Relief Association
Osaka Medical Center for Cancer and Cardiovascular Diseases
Osaka Medical College Hospital
Osaka Police Hospital
Osaka Prefectural Hospital Organization Osaka General Medical Center
Osaka University Hospital
Otsu Municipal Hospital
Otsu Red Cross Hospital
Rinku General Medical Center
Ryukyu University Hospital
Saga-ken Medical Center Koseikan
Saiseikai Fukushima General Hospital
Saiseikai Hiroshima Hospital
Saiseikai Kyoto Hospital
Saiseikai Yahata General Hospital
Saitama Cancer Center
Saitama City Hospital
Saitama Medical Center
Saitama Medical University Hospital
Saitama Medical University Saitama International Medical Center
Saitama Medical University Saitama Medical Center
Sakai City Medical Center
Saku Central Hospital
Sanin Rosai Hospital
Sano Kousei General Hospital
Sendai City Hospital
Sendai Medical Center
Shiga Medical Center for Adults
Shiga University of Medical Science Hospital
Shikoku Cancer Center
Shimada Hospital
Shimane University Hospital
Shimizu Welfare Hospital
Shinshu University Hospital
Shizuoka Cancer Center
Shizuoka City Shizuoka Hospital
Shizuoka General Hospital
Showa University Fujigaoka Hospital
Showa University Hospital
Showa University Koto-Toyosu Hospital
Showa University Northern Yokohama Hospital
Social Insurance Omuta Tenryo Hospital
Social Insurance Tagawa Hospital
St. Marianna University School of Medical Hospital
St. Luke’s International Hospital
Sugita Genpaku Memorial Obama Municipal Hospital
Suita Municipal Hospital
Takasago Municipal Hospital
Takatsuki Red Cross Hospital
Takeda Hospital
Teikyo University Hospital
Teikyo University Hospital, Mizonokuchi
Tenri Hospital
The Cancer Institute Hospital of JFCR
The Jikei University Hospital
The Research Center Hospital for Charged Particle Therapy of NIRS
Tochigi Medical Center
Toho University Omori Medical Center
Toho University Sakura Medical Center
Tohoku Kosai Hospital
Tohoku University Hospital
Tokai University Hospital
Tokushima Municipal Hospital
Tokushima Prefectural Naruto Hospital
Tokushima Red Cross Hospital
Tokushima University Hospital
Tokyo Dental College Ichikawa General Hospital
Tokyo Medical and Dental University Hospital
Tokyo Medical University Hospital
Tokyo Medical University Ibaraki Medical Center
Tokyo Metropolitan Health and Medical Corporation Toshima Hospital
Tokyo University Hospital
Tokyo Women’s Medical University Hospital
Tokyo Women’s Medical University Medical Center East
Tonan Hospital
Toranomon Hospital
Tottori Prefectural Central Hospital
Tottori University Hospital
Toyama Prefectural Central Hospital
Toyama University Hospital
Toyonaka Municipal Hospital
Tsuchiura Kyodo Hospital
Tsukuba University Hospital
Tsuruoka Municipal Shonai Hospital
University Hospital, Kyoto Prefectural University of Medicine
University of Miyazaki Hospital
Wakayama Medical University Hospital
Yamagata Prefectural and Sakata Municipal Hospital Organization
Yamagata Prefectural Central Hospital
Yamagata Prefectural Shinjo Hospital
Yamaguchi University Hospital
Yamaguchi-ken Saiseikai Shimonoseki General Hospital
Yamanashi Prefectural Central Hospital
Yamanashi University Hospital
Yao Municipal Hospital
Yokohama Chuo Hospital
Yokohama City Municipal Hospital
Yokohama City University Hospital
Yokohama City University Medical Center
Yuri General Hospital

(Total 280 institutions)

  38 in total

1.  Prognosis and prognostic factors of esophageal spindle cell carcinoma treated by esophagectomy: a retrospective single-institution analysis.

Authors:  Masashi Hashimoto; Hidehiko Kitagami; Hiroki Niwa; Tomohiro Kikkawa; Tomoyuki Ohuchi; Toshinao Takenouchi; Masao Hosokawa
Journal:  Esophagus       Date:  2019-04-01       Impact factor: 4.230

2.  Molecular and clinicopathological analyses of esophageal carcinosarcoma with special reference to morphological change.

Authors:  Sho Tsuyama; Tsuyoshi Saito; Yoichi Akazawa; Yuka Yanai; Noboru Yatagai; Keisuke Akaike; Takuo Hayashi; Yoshiyuki Suehara; Fumiyuki Takahashi; Kazuya Takamochi; Takashi Hashimoto; Yoshiaki Kajiyama; Masahiko Tsurumaru; Tetsu Fukunaga; Takashi Yao
Journal:  Virchows Arch       Date:  2019-08-23       Impact factor: 4.064

3.  Current status of radiotherapy for patients with thoracic esophageal cancer in Japan, based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society.

Authors:  Yasushi Toh; Hodaka Numasaki; Yuji Tachimori; Takashi Uno; Keiichi Jingu; Kenji Nemoto; Hisahiro Matsubara
Journal:  Esophagus       Date:  2019-08-31       Impact factor: 4.230

4.  Prognostic significance of platelet × C-reactive protein multiplier in patients with esophageal squamous cell carcinoma.

Authors:  Yuji Shishido; Hiroaki Saito; Shota Shimizu; Yusuke Kono; Yuki Murakami; Kozo Miyatani; Tomoyuki Matsunaga; Manabu Yamamoto; Yoji Fukumoto; Soichiro Honjo; Yoshiyuki Fujiwara
Journal:  Surg Today       Date:  2019-08-30       Impact factor: 2.549

Review 5.  Comparison of two major staging systems of esophageal cancer-toward more practical common scale for tumor staging.

Authors:  Harushi Udagawa; Masaki Ueno
Journal:  Ann Transl Med       Date:  2018-02

6.  Optimized lymph node dissection range during progression of lower thoracic esophageal squamous cell carcinoma in the latest therapeutic surgical strategy: A retrospective analysis.

Authors:  Hiroki Harada; Kei Hosoda; Hiromitsu Moriya; Hiroaki Mieno; Akira Ema; Marie Washio; Yoshimasa Kosaka; Masahiko Watanabe; Keishi Yamashita
Journal:  Oncol Lett       Date:  2018-06-27       Impact factor: 2.967

7.  Clinical Utility of ypTNM Stage Grouping in the 8th Edition of the American Joint Committee on Cancer TNM Staging System for Esophageal Squamous Cell Carcinoma.

Authors:  Natsuru Sudo; Hiroshi Ichikawa; Yusuke Muneoka; Takaaki Hanyu; Yosuke Kano; Takashi Ishikawa; Yuki Hirose; Kohei Miura; Yoshifumi Shimada; Masayuki Nagahashi; Jun Sakata; Takashi Kobayashi; Takeo Bamba; Satoru Nakagawa; Shin-Ichi Kosugi; Toshifumi Wakai
Journal:  Ann Surg Oncol       Date:  2020-10-06       Impact factor: 5.344

8.  Expression of kallikrein-related peptidase 13 is associated with poor prognosis in esophageal squamous cell carcinoma.

Authors:  Kyoko Nohara; Kazuhiko Yamada; Leo Yamada; Teruki Hagiwara; Toru Igari; Chizu Yokoi; Daisuke Soma; Satoshi Yamashita; Taeko Dohi; Yuki I Kawamura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-03-26

Review 9.  Current status of cancer immunotherapy for esophageal squamous cell carcinoma.

Authors:  Koji Kono; Kousaku Mimura; Reo Yamada; Daisuke Ujiie; Suguru Hayase; Takeshi Tada; Hiroyuki Hanayama; Aung Kyi Thar Min; Masahiko Shibata; Tomoyuki Momma; Zenichirou Saze; Shinji Ohki
Journal:  Esophagus       Date:  2017-11-27       Impact factor: 4.230

10.  Long-term outcomes of multimodal therapy combining definitive chemoradiotherapy and salvage surgery for T4 esophageal squamous cell carcinoma.

Authors:  Kotaro Sugawara; Koichi Yagi; Yasuhiro Okumura; Masato Nishida; Susumu Aikou; Hiroharu Yamashita; Hideomi Yamashita; Yasuyuki Seto
Journal:  Int J Clin Oncol       Date:  2019-12-11       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.